Relay Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $9.36M, a 96.71% decline year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $284.74M.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $425.29M.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $30.28M, a 89.37% decline from fiscal 2022.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $284.74M, a 25.50% decline from fiscal 2021.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $382.21M, a 10.13% decline from fiscal 2020.
- Relay Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $425.29M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $30.28M 10-K · filed 2024-02-22 | |
| 2023-09-30 | $9.36M 10-Q · filed 2023-11-02 | |
| 2022-12-31 | $284.74M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $284.74M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $382.21M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $425.29M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $425.29M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |